Delivery Order SPE2DB24D2106-SPE2DB25FAVZE
- Not listed
- This is a delivery order contract (SPE2DB20D6037|SPE2DB25FTUE9) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,051.36 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $1,314.20, is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a period of performance through May 13, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the agency to issue...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,366.07 contract is for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a performance period ending on May 20, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery orders for a...
- This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles, with a ceiling value of $2,412.14 and a completion date of July 3, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois that specializes in providing a range of pharmaceutical products to federal...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois, is a firm fixed-price delivery order under the SPE2DB program with the Defense Logistics Agency (DLA). The $1,883.83 award is for the medication Quillivant XR 25 mg/5 ml suspension, 120 ml, with a performance period ending on May 21, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a diverse portfolio of branded and...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,303.87 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business in Park Ridge, Illinois. The contract is for the supply of Quillivant XR 25 mg/5 mL suspension, a pharmaceutical product. This delivery order is part of a larger indefinite delivery contract valued up to $4,999,999 held by DMS Pharmaceutical Group with DLA, contract number SPE2DB24D2106, which allows DLA to issue delivery orders for a...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, 120 ml, with a ceiling value of $3,379.20 and a completion date of June 11, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The $5,393.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the SPE2DB24 indefinite delivery contract, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. This single-award IDC allows the DLA to issue delivery orders for a...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAVZEDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,231.66 by the Defense Logistics Agency on August 12, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The contract carries no set-aside designation and is scheduled for completion by August 13, 2025, with performance to take place in Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, which is valued at approximately $500 million and remains valid through November 2026. The SPE2DB Indefinite Delivery Contract enables the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting the medical supply needs of Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to military and federal healthcare systems. The company's portfolio includes specialty medications such as oncology treatments, auto-injectors, vaccines, and contraceptive devices, positioning it as a key distributor of prescription pharmaceuticals and pharmacy services to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/12/25 |